Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma

Stevens-Johnsons syndrome (SJS) is a rare but life-threatening cutaneous adverse reaction mainly elicited by exposure to certain drugs, including epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and immunotherapies [1 –3]. Nivolumab has been widely used for treating lung cancer and has been reported to cause this devastating adverse event and warrants permanent medication termination [4]. Nevertheless, immunotherapy itself may not always be the culprit medication but, rather, might simply be an enhancer of immu nologic reactions in another drug-induced SJS.

Source: Lung Cancer - September 4, 2020 Category: Cancer & Oncology Authors: Yi-Tsz Lin, James Chih-Hsin Yang, Chia-Yu Chu Source Type: research